April 24, 2010 (FinancialWire) — Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM), a China-based manufacturer of an over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules and other pharmaceutical products, said it has been approved by NASDAQ to list its common stock on the NASDAQ Global Market.

The company said its listing application was reviewed and approved by NASDAQ's Listing Qualifications Department for compliance with all of NASDAQ's standards.

Biostar’s common stock will begin trading on the NASDAQ Global Market under the ticker symbol BSPM on April 23, 2010.

China-based Biostar Pharmaceuticals, through its wholly owned subsidiary in China, develops, manufactures and markets pharmaceutical products for a range of diseases and conditions. The company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter medicine for chronic hepatitis B, a disease affecting around 10% of the Chinese population.

Streaming Research for all companies mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [rgltryrtl] [cmplncz] [gvrncnr] [chnchn] [ntrntnlcmpnsbsnss] [lstngsnws]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.